NASDAQ:PACB - Pacific Biosciences of California Stock Price, Price Target & More

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.01. The biotechnology company earned $19.40 million during the quarter, compared to analysts' expectations of $23.97 million. Pacific Biosciences of California had a negative return on equity of 91.11% and a negative net margin of 105.22%. Pacific Biosciences of California's quarterly revenue was down 22.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.26) EPS. View Pacific Biosciences of California's Earnings History.

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacific Biosciences of California.

2 brokerages have issued twelve-month price targets for Pacific Biosciences of California's shares. Their predictions range from $4.00 to $6.80. On average, they expect Pacific Biosciences of California's share price to reach $5.40 in the next year. View Analyst Ratings for Pacific Biosciences of California.

Some companies that are related to Pacific Biosciences of California include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), pSivida (EYPT), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Arrayit Corp common stock (ARYC), Precipio (PRPO), Scientific Industries (SCND), Pressure Biosciences (PBIO) and PositiveID (PSID).

Media stories about PACB stock have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a media sentiment score of 0.04 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.55 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Pacific Biosciences of California's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.67%), Blackstone Group L.P. (3.13%), Point72 Asset Management L.P. (1.59%), Northern Trust Corp (1.00%), Trellus Management Company LLC (0.59%) and Schwab Charles Investment Management Inc. (0.39%). View Institutional Ownership Trends for Pacific Biosciences of California.

PACB stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Pacific Biosciences of California.

PACB stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Blackstone Group L.P., BlackRock Inc., Citadel Advisors LLC, Millennium Management LLC, UBS Group AG, Trellus Management Company LLC and Northern Trust Corp. View Insider Buying and Selling for Pacific Biosciences of California.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $2.58.

Pacific Biosciences of California has a market capitalization of $344.20 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]